InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn's Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease ("GERD")

IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently meets the other continued listing requirement, including the minimum market value of publicly held shares, as well as all other applicable requirements for initial listing on the NASDAQ Capital Marke

Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from www.infoodsIBS.com without needing to visit a doctor's officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly

Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce Annual Expenses by 16% to 23%, Representing $1.0 to $1.4 Million ReductionBiomerica's At-Home PSA Screening Test Receives Saudi Food and Drug Authority (SFDA) Approval for Early Detection of Prostate Cancer IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024. Key Highlights: Saudi FDA Approval for At-Home PSA Scree

- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test is designed to empower men with the ability to detect early warning signs of prostate cancer from the comfort of their own homes. The Fortel® Prostate (PSA) At-Home Screening Test is a user-friendly, rapid diagnostic tool that m

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger GrowthSignificant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $1.0 to $1.4 Million in the Coming YearinFoods® IBS Pilot with Large 1,100 Physician Group Progressing Ahead of Schedule IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tes

inFoods® IBS patients can now conveniently self-collect a blood sample using a simple finger-stick methodology in the privacy of their home inFoods® IBS test is the first of its kind to identify specific foods that can trigger an Irritable Bowel Syndrome (IBS) symptoms IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience. Empowering Patients & Physicians Through Self-Collection The inFoods® IBS diagnostic test has made a significant advancement with the in

With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis by all physicians, IBS represents a significant healthcare burden. inFoods IBS offers a groundbreaking method to identify foods that can trigger IBS symptoms, revolutionizing how IBS symptoms are managed. inFoods IBS is backed by extensive clinical research that has demonstrated remarkable efficacy in providing relief to the majority of IBS patients. The upcoming presentation of positive inFoods IBS clinical data during the IBS Clinical Session at the Digestive Disease Week

Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica's EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breastsFirst order placed for both Colon Disease and Breast screening products IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), is proud to announce a multi-year exclusive distribution agreement with o

- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issued/allowed patents. IRVINE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products is pleased to announce advanc

8-K - BIOMERICA INC (0000073290) (Filer)

10-Q - BIOMERICA INC (0000073290) (Filer)

DEF 14A - BIOMERICA INC (0000073290) (Filer)

PRE 14A - BIOMERICA INC (0000073290) (Filer)

10-K - BIOMERICA INC (0000073290) (Filer)

8-K - BIOMERICA INC (0000073290) (Filer)

424B5 - BIOMERICA INC (0000073290) (Filer)

8-K - BIOMERICA INC (0000073290) (Filer)

10-Q - BIOMERICA INC (0000073290) (Filer)

10-Q - BIOMERICA INC (0000073290) (Filer)

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin

Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for the Rome IV Committee on Functional Bowel Disorders. Dr. Lacy has authored over 225 peer reviewed articles IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA) (the "Company") appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginni